2026-10-19T01:03:54Zhttps://ebyu-rdlopen.rawdatalibrary.net/oai/request

oai:ebyu-rdlopen.rawdatalibrary.net:ebyu/151812026-10-18T20:43:08Zopenairedrivercom_ebyu_10000col_ebyu_10001

Does neoadjuvant chemotherapy plus cytoreductive surgery improve survival rates in patients with advanced epithelial ovarian cancer compared with cytoreductive surgery alone?Solmaz, UlasMat, EmreDereli, Murat LeventTuran, VolkanPeker, NuriTosun, GokhanDogan, AskinAdiyeke, MehmetOzdemir, AykutGungorduk, KemalSanci, MuzafferYildirim, YusufNeoadjuvant chemotherapyOvarian cancerPrimary debulking surgerySurvivalAgedAntineoplastic Combined Chemotherapy ProtocolsCarboplatinChemotherapy, AdjuvantCytoreduction Surgical ProceduresDisease-Free SurvivalFemaleHumansKaplan-Meier EstimateMiddle AgedMultivariate AnalysisNeoadjuvant TherapyNeoplasm StagingNeoplasms, Glandular and EpithelialOvarian NeoplasmsPaclitaxelPatient SelectionProportional Hazards ModelsRetrospective StudiesRisk FactorsTaxoidsTime FactorsTreatment OutcomeCA 125 antigendocetaxelantineoplastic agentPurpose: The purpose of this study was to compare the outcomes of interval debulking surgery after neoadjuvant chemotherapy (NAC/IDS) with primary debulking surgery (PDS) in patients diagnosed with advanced epithelial ovarian cancer (EOC). Methods: A total of 292 patients with IIIC and IV disease stages, who were treated with either NAC/IDS or PDS between 1995 and 2012 were retrospectively reviewed. The study population was divided into two groups: the NAC/IDS group (N=84) and the PDS group (N=208). Progression-free survival (PFS), overall survival (OS), and optimal cytoreduction were compared. Results: The mean patient age was significantly higher in the NAC/IDS group (61.5±11.5 vs 57.8±11.1, p=0.01). Optimal cytoreduction was achieved in 34.5% (29/84) of the patients in the NAC/IDS group and in 32.2% (69/208) in the PDS group (p=0.825). The survival rates were comparable. The survival rate of patients who received optimal cytoreductive surgery in either the PDS or the NAC/IDS arm was significantly higher than that of patients who received suboptimal cytoreductive surgery (p<0.01 and p<0.01, respectively). Multivariate analysis confirmed the treatment method, amount of ascitic fluid, and optimal cytoreduction as independent factors for OS. Conclusions: There was no definitive evidence regarding whether NAC/IDS increases survival rates compared with PDS. NAC should be reserved for patients who cannot tolerate PDS or when optimal cytoreduction is not feasible.Zerbinis Publications2015Articlehttps://rdlopen.rawdatalibrary.net/r/ebyu/151811107-0625enJournal of B.U.ON.info:eu-repo/semantics/openAccessinfo:eu-repo/semantics/articlehttps://ebyu-rdlopen.rawdatalibrary.net/tr/items/ebyu/15181